store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GMB-475 是一种基于PROTAC 的BCR-ABL1酪氨酸激酶降解剂,克服了BCR-ABL1依赖的耐药性。 GMB-475 靶向 BCR-ABL1 蛋白并募集 E3 连接酶 Von Hippel Lindau (VHL)。导致泛素化和随后的致癌融合蛋白降解
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 488 | 现货 | ||
5 mg | ¥ 1,070 | 现货 | ||
10 mg | ¥ 1,730 | 现货 | ||
25 mg | ¥ 3,150 | 现货 | ||
50 mg | ¥ 4,630 | 现货 | ||
100 mg | ¥ 6,490 | 现货 | ||
500 mg | ¥ 12,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,650 | 现货 |
产品描述 | GMB-475 is a BCR-ABL1 tyrosine kinase degrader based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL).resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein |
体外活性 | GMB-475 inhibited the proliferation of certain clinically relevant BCR-ABL1 kinase domain point mutants and further sensitized Ba/F3 BCR-ABL1 cells to inhibition by imatinib, while demonstrating no toxicity toward Ba/F3 parental cells.?Reverse phase protein array analysis suggested additional differences in levels of phosphorylated SHP2, GAB2, and SHC associated with BCR-ABL1 degradation.?Importantly, GMB-475 reduced viability and increased apoptosis in primary CML CD34+ cells, with no effect on healthy CD34+ cells at identical concentrations.?GMB-475 degraded BCR-ABL1 and reduced cell viability in primary CML stem cells.?Together, these findings suggest that combined BCR-ABL1 kinase inhibition and protein degradation may represent a strategy to address BCR-ABL1-dependent drug resistance, and warrant further investigation into the eradication of persistent leukemic stem cells, which rely on neither the presence nor the activity of the BCR-ABL1 protein for survival. |
分子量 | 861.93 |
分子式 | C43H46F3N7O7S |
CAS No. | 2490599-18-1 |
store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 95 mg/mL (110.22 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.1602 mL | 5.8009 mL | 11.6019 mL | 29.0047 mL |
5 mM | 0.232 mL | 1.1602 mL | 2.3204 mL | 5.8009 mL | |
10 mM | 0.116 mL | 0.5801 mL | 1.1602 mL | 2.9005 mL | |
20 mM | 0.058 mL | 0.29 mL | 0.5801 mL | 1.4502 mL | |
50 mM | 0.0232 mL | 0.116 mL | 0.232 mL | 0.5801 mL | |
100 mM | 0.0116 mL | 0.058 mL | 0.116 mL | 0.29 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GMB-475 2490599-18-1 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl PROTACs Apoptosis Inhibitor inhibit GMB475 GMB 475 inhibitor